Posted by Michael Wonder on 17 Jan 2024
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
16 January 2024 - Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possible.
Roche announced today that the European Commission has granted marketing authorisation for Tecentriq SC (atezolizumab), the European Union’s first PD-(L)1 cancer immunotherapy for subcutaneous injection.
